These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 15764271

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.
    Guichard G, Larré S, Gallina A, Lazar A, Faucon H, Chemama S, Allory Y, Patard JJ, Vordos D, Hoznek A, Yiou R, Salomon L, Abbou CC, de la Taille A.
    Eur Urol; 2007 Aug; 52(2):430-5. PubMed ID: 17412489
    [Abstract] [Full Text] [Related]

  • 4. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM.
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [Abstract] [Full Text] [Related]

  • 5. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 6. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones.
    Sakai I, Harada K, Kurahashi T, Yamanaka K, Hara I, Miyake H.
    Int J Urol; 2006 Apr; 13(4):368-72. PubMed ID: 16734852
    [Abstract] [Full Text] [Related]

  • 7. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H, Kajita Y, Shimizu Y, Yamauchi T.
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [Abstract] [Full Text] [Related]

  • 8. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H.
    Prostate; 2005 Apr 01; 63(1):13-8. PubMed ID: 15378521
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 11. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F.
    Ann Clin Lab Sci; 2003 Feb 01; 33(3):320-3. PubMed ID: 12956448
    [Abstract] [Full Text] [Related]

  • 12. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
    Ohigashi T, Kanao K, Kikuchi E, Nakagawa K, Nakashima J, Marumo K, Murai M.
    J Urol; 2005 May 01; 173(5):1541-5. PubMed ID: 15821482
    [Abstract] [Full Text] [Related]

  • 13. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y.
    Hinyokika Kiyo; 1999 Jul 01; 45(7):457-61. PubMed ID: 10466060
    [Abstract] [Full Text] [Related]

  • 14. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B, Alkibay T, Tuncel A, Bozkirli I.
    Can J Urol; 2000 Oct 01; 7(5):1104-9. PubMed ID: 11114873
    [Abstract] [Full Text] [Related]

  • 15. Is extended 11-core biopsy valuable in benign prostatic hyperplasia patients with intermediate serum prostate-specific antigen (4.1-10 ng/ml) and prior negative sextant biopsy?
    Abdel-Khalek M, El-Baz M, Ibrahiem el-H.
    Scand J Urol Nephrol; 2004 Oct 01; 38(4):315-20. PubMed ID: 15669591
    [Abstract] [Full Text] [Related]

  • 16. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
    Keetch DW, Catalona WJ.
    J Urol; 1995 Nov 01; 154(5):1795-7. PubMed ID: 7563349
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
    Sakai I, Harada K, Hara I, Eto H, Miyake H.
    BJU Int; 2005 Sep 01; 96(4):528-32. PubMed ID: 16104904
    [Abstract] [Full Text] [Related]

  • 18. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
    Abdel-Khalek M, El-Baz M, Ibrahiem el-H.
    BJU Int; 2004 Sep 01; 94(4):528-33. PubMed ID: 15329106
    [Abstract] [Full Text] [Related]

  • 19. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
    Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM.
    Cancer Res; 2000 Feb 01; 60(3):756-9. PubMed ID: 10676664
    [Abstract] [Full Text] [Related]

  • 20. [Prostate cancer in the transition zone in sympatomatic patients with no rectal signs and negative peripheral zone biopsy].
    Herranz Amo F, Díez Cordero JM, Verdú Tartajo F, Bueno Chomón G, Leal Hernández F, Bielsa Carrillo A, García Burgos J.
    Arch Esp Urol; 1998 Jun 01; 51(5):437-41. PubMed ID: 9675938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.